All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Treatment sequencing for anemic myelofibrosis
with Jean-Jacques Kiladjian & Angela Fleischman
Monday, February 26, 2024 | 16:30 CET
This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
Bookmark this article
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Ghaith Abu-Zeinah, Weill Cornell Medicine, New York, US. We asked, Does interferon alpha prolong survival and prevent progression in patients with polycythemia vera (PV)?
Does interferon alpha prolong survival and prevent progression in patients with PV?
PV is a disease associated with shorter survival due to short-term complications, such as thrombosis, and long-term complications of progression to myelofibrosis and transformation to acute leukemia, which are associated with poor prognosis. The current treatment guidelines for PV recommend phlebotomy only for low-risk patients and, for a long time, these guidelines favored hydroxyurea over interferon alfa for the initial treatment of high-risk patients.
In this podcast, Abu-Zeinah shares the key findings of a retrospective study comparing myelofibrosis-free survival and overall survival of 470 patients with PV treated with recombinant interferon alfa, hydroxyurea, or phlebotomy only.
DALIAH final analysis: Pegylated IFNα-2 vs hydroxyurea
Here, we summarize a presentation by Knudsen from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition on the final analysis of the phase III DALIAH trial.
Mutations in JAK2, CALR, and MPL and the effect on response to IFNα in MPN
Classical BCR-ABL1-negative myeloproliferative neoplasms (MPN), including primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET), are typically...
Subscribe to get the best content related to MPN delivered to your inbox